Evidence map›Paper›PMID 26467221›Full record

ArticleTissue engineering. Part C, Methods2016

An In Vitro Investigation of Platelet-Rich Plasma-Gel as a Cell and Growth Factor Delivery Vehicle for Tissue Engineering.

Jagoda M Jalowiec, Matteo D'Este, Jennifer Jane Bara, Jessica Denom, Ursula Menzel, Mauro Alini, Sophie Verrier, Marietta Herrmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue engineering. Part C, Methods, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jagoda M Jalowiec1 AO Research Institute Davos , Davos, Switzerland .
Matteo D'Este1 AO Research Institute Davos , Davos, Switzerland .
Jennifer Jane Bara1 AO Research Institute Davos , Davos, Switzerland .
Jessica Denom2 Biologie Fonctionnelle et Adaptative, CNRS UMR 8251, Université Paris Diderot Paris 7 , Paris, France .
Ursula Menzel1 AO Research Institute Davos , Davos, Switzerland .
Mauro Alini1 AO Research Institute Davos , Davos, Switzerland .
Sophie Verrier1 AO Research Institute Davos , Davos, Switzerland .
Marietta Herrmann1 AO Research Institute Davos , Davos, Switzerland .

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet-rich plasma (PRP) has been used for different applications in human and veterinary medicine. Many studies have shown promising therapeutic effects of PRP; however, there are still many controversies regarding its composition, properties, and clinical efficacy. The aim of this study was to evaluate the influence of different platelet concentrations on the rheological properties and growth factor (GF) release profile of PRP-gels. In addition, the viability of incorporated bone marrow-derived human mesenchymal stem cells (MSCs) was investigated. PRP (containing 1000 × 10(3), 2000 × 10(3), and 10,000 × 10(3) platelets/μL) was prepared from human platelet concentrates. Platelet activation and gelification were achieved by addition of human thrombin. Viscoelastic properties of PRP-gels were evaluated by rheological studies. The release of GFs and inflammatory proteins was measured using a membrane-based protein array and enzyme-linked immunosorbent assay. MSC viability and proliferation in PRP-gels were assessed over 7 days by cell viability staining. Cell proliferation was examined using DNA quantification. Regardless of the platelet content, all tested PRP-gels showed effective cross-linking. A positive correlation between protein release and the platelet concentration was observed at all time points. Among the detected proteins, the chemokine CCL5 was the most abundant. The greatest release appeared within the first 4 h after gelification. MSCs could be successfully cultured in PRP-gels over 7 days, with the highest cell viability and DNA content found in PRP-gels with 1000 × 10(3) platelets/μL. The results of this study suggest that PRP-gels represent a suitable carrier for both cell and GF delivery for tissue engineering. Notably, a platelet concentration of 1000 × 10(3) platelets/μL appeared to provide the most favorable environment for MSCs. Thus, the platelet concentration is an important consideration for the clinical application of PRP-gels.

Indexed as

Tissue ScaffoldsBiocompatible MaterialsCells, CulturedCell SurvivalDiffusionDrug ImplantsElastic ModulusGelsHumansIntercellular Signaling Peptides and ProteinsMaterials TestingMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPlatelet-Rich PlasmaTissue EngineeringViscosityBiocompatible MaterialsDrug ImplantsGelsIntercellular Signaling Peptides and Proteins

Identifiers

PMID26467221
PMCPMC4722608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.